Cambridge, MA - July 28, 2009

Cerulean Pharma Inc. Closes $10 Million Series B-1 Financing - Company Appoints Acting Chief Medical Officer, John Ryan, to advance clinical trial with lead nanopharmaceutical product candidate.

Cerulean Pharma Inc., a biopharmaceutical company focused on novel intelligently designed nanoparticle-based drugs, today announced that it has closed a $10 million Series B-1 financing. More >>


Cerulean Pharma
Pioneering the Field of Nanobiology


Nanopharmaceuticals are a revolutionary new approach to designing drugs within ultra-small particles and enhancing their properties with the goal of creating improved therapies for fighting disease.

Within the field of nanopharmaceuticals, Cerulean Pharma is uniquely focused on a next-generation approach we call Nanobiology. Cerulean’s nanobiology-based drug development is based on a deep understanding of the complex biological microenvironment of human disease combined with engineering therapies on a nanoscale, enabling the creation of breakthrough drugs that optimally target the root causes of disease.


Conventional Chemotherapy
vs
Nanopharmaceutical Chemotherapy


View Movie

Company :: Technology :: Careers :: News :: Contact :: Home :: Privacy Policy :: Terms & Conditions of Use
Cerulean Pharma, Inc. :: 840 Memorial Drive, 5th Floor, Cambridge, MA 02142  ::   p 617 551 9600 ::   f 617 494 1544
Copyright 2009 © Cerulean Pharma, Inc. All rights reserved.